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Periostin as a novel biomarker for 
postoperative recurrence of chronic 
rhinosinitis with nasal polyps
Takahiro Ninomiya1, Emiko Noguchi2, Takenori Haruna3, Masayo Hasegawa4, 
Takuto Yoshida5, Yukiko Yamashita6, Mitsuhiro Okano7, Naohiro Yoshida4, Shinichi Haruna5, 
Yasunori Sakuma6, Shoichiro Ohta8, Junya Ono9,10, Kenji Izuhara8, Masafumi Okada11, 
Masanori Kidoguchi1, Takahiro Tokunaga1, Masayuki Okamoto1, Masafumi Kanno1, 
Masafumi Sakashita1, Tetsuji Takabayashi1, Norihiko Narita1 & Shigeharu Fujieda1
We previously reported that chronic rhinosinusitis with nasal polyps (CRSwNP) was subdivided into 
four chronic rhinosinusitis (CRS) subtypes using the JESREC scoring system. We sought to identify the 
gene expression profile and biomarkers related with CRSwNP by RNA-sequence. RNA-sequencing was 
performed to identify differentially expressed genes between nasal polyps (NPs) and inferior turbinate 
mucosa from 6 patients with CRSwNP, and subsequently, quantitative real-time PCR was performed to 
verify the results. ELISA was performed to identify possible biomarkers for postoperative recurrence. 
In the RNA-sequencing results, periostin (POSTN) expression was the highest in NP. We focused on 
POSTN and investigated the protein level of POSTN by immunohistochemistry and ELISA. POSTN 
was diffusely expressed in moderate and severe eosinophilic CRS using immunohistochemistry, and its 
staining pattern was associated with the severity of the phenotype of the CRSwNP (P < 0.05). There 
was a significant difference between the POSTN high/low groups for postoperative recurrence when the 
cutoff point was set at 115.5 ng/ml (P = 0.0072). Our data suggests that the protein expression level of 
POSTN was associated with the severity of CRSwNP, and serum POSTN can be a novel biomarker for 
postoperative recurrence of CRSwNP.
Chronic rhinosinusitis (CRS) is one of the most common diseases worldwide. The prevalence of CRS is 10–14% 
in Europe and the US, and the economic burden was estimated at approximately 60 billion US dollars in 20111,2. 
In East Asia, the prevalence of CRS is 5–10%, almost equivalent with Europe and the US3. In the guidelines of 
a European position paper on rhinosinusitis and nasal polyps in 2012 (EPOS 2012), rhinosinusitis is diagnosed 
based on symptoms, physical examination and radiographic findings: nasal obstruction, nasal discharge, endo-
scopic signs of nasal polyps (NPs) and mucopurulent discharge, and CT changes2. CRS is defined as the condi-
tion with the symptoms and examination findings lasting for more than 12 weeks2. CRS is categorized by being 
positive or negative of NPs; chronic rhinosinusitis with NPs (CRSwNP) and chronic rhinosinusitis without NPs 
(CRSsNP)2. In Western countries, most of the CRSwNP belong to eosinophilic CRS (ECRS), which is defined as 
>5 or >10 eosinophils per high-power field (HPF), and has been categorized to eosinophilic dominant inflam-
mation4,5. Eosinophilic inflammation in CRS is considered to be reflected by the severity and poor outcome with 
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treatment6,7. In contrast, in East Asia, CRSwNP has been reported to be neutrophil dominant inflammation6. 
Recently, however, we reported that the proportion of the eosinophil dominant type of CRSwNP in Japan was 
nearly equal to that in the Western countries7. We also reported that CRSwNP was subdivided into four subtypes; 
non-ECRS, mild ECRS, moderate ECRS and severe ECRS by using the scoring system based on one/both sides 
of disease, presence of NPs, ethmoid dominant CT shadow, and eosinophil ratio in peripheral blood (Japanese 
Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study: JESREC Study)7.
CRSwNP is considered to be related to Th2 dominant inflammation mainly with eosinophil infiltration8. 
Many genes related to eosinophilic recruitment and activation were reported to be upregulated in CRSwNP (e.g., 
C-C motif chemokine ligand 18 (CCL18), CCL23 and interleukin 32 (IL32)9–11. Epithelial cell cytokines may have 
an important role for eosinophil and Th2 type cell recruitment at the local site, for example thymic stromal lym-
phopoietin (TSLP) and IL33 were essential for dendritic cell polarization and T cell differentiation8,12–14. Although 
some genes were found to be associated with mucosal inflammation and epithelial repair in CRS, the pathogenic 
mechanism of CRS has not been well elucidated.
Gene profiling technology such as microarray and serial analysis of gene expression (SAGE) can identify novel 
genes related to disease condition by comparing the global gene expression profile in normal tissues with that in 
diseased15. Liu et al. reported 19 upregulated genes and 8 downregulated genes in NPs compared with the tissue 
from the uncinate process from patients undergoing septoplasty using microarray16. The most upregulated gene 
by microarray was osteopontin, which is involved in the pathogenesis of inflammatory and immune responses, 
with osteopontin being found to play roles in promoting eosinophil migration and activation in vitro16. Li et al. 
examined expression levels of NPs and inferior turbinate (IT) obtained from CRS patients mucosa using microar-
ray, and focused on the genes associated with regulatory T cell (T-reg) and helper T cell (Th cell)17. Forkhead box 
P3 (FOXP3) which is essential for T-reg development was upregulated in NPs compared with that in IT, and genes 
associated with Th2 (GATA binding protein 3: GATA3) or Th17 response (RAR related orphan receptor C: RORC) 
were downregulated in NPs17. Lee et al. reported the highest expression tags in NPs with SAGE were interferon 
induced protein with tetratricopeptide repeats 3 (IFIT3), CD74, Lipocalin 2 (LCN2) and TYRO protein tyrosine 
kinase binding protein (TYROBP)15.
RNA sequencing (RNA-seq) is an innovative technology that uses a next-generation sequencer to sequence 
all transcripts including mRNAs, non-coding RNAs and small RNAs18. The primal purpose of RNA-seq is to 
measure the expression levels of each transcript, particularly to identify new genes/transcripts, under different 
conditions18–20. In contrast to microarray and SAGE, RNA-seq can detect the transcripts for a large dynamic range 
of expression levels with very low background signal18,19. Actually, RNA-seq has identified many genes that could 
be used as a biomarker for diseases such as cancer19,21 and asthma22.
In this study, we used RNA-seq to compare the expression profile in NPs obtained from patients with CRSwNP 
with that in IT mucosa from the same patients. Quantitative real time PCR (qPCR) was used to confirm the initial 
results obtained by RNA-seq. Then, we focused on periostin (POSTN) whose expression level was the highest 
in NPs, and immunohistochemical analysis was performed to evaluate the protein expression level of POSTN 
in NPs. The association between serum POSTN level and postoperative recurrence was also investigated to see 
whether serum POSTN is a possible biomarker for postoperative recurrence.
Results
Transcriptome analysis. Figure 1 shows the flowchart of the present study, and characteristics of study 
subjects are described in Table 1. Patients were subdivided according to the JESREC scoring system, as described 
previously, into non-ECRS, mild ECRS, moderate ECRS and severe ECRS groups7. We analyzed the gene expres-
sions in 6 samples of NP with CRSwNP using RNA-seq, and compared the expression levels in NP with those in 
IT obtained from the same patients. When comparing the expression levels between NP and IT, 3,574 transcripts 
were statistically significantly different (q < 0.05). Of these, 1,264 transcripts were upregulated in NP with log fold 
changes (logFC) > 1 (Supplementary Table S1), and 899 transcripts were downregulated in NP with logFC < −1 
(Supplementary Table S2). We focused on the 5 most upregulated and 5 most downregulated genes that were 
highly expressed in NP. These 10 genes expression levels in the RNA-seq group obtained from RNA-seq are shown 
in Table 2. To confirm the RNA-seq results, qPCR analysis was performed using the same samples (6 patients used 
Figure 1. Flowchart of the present study. RNA-seq, RNA sequencing; qPCR, quantitative real-time PCR; CRS, 
chronic rhinosinusitis.
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in RNA-seq study), and the results of qPCR were concordant with those of RNA-seq (Supplementary Fig. S2). 
Furthermore, we analyzed these 10 genes expression levels in NP/IT in replication group using qPCR. We per-
formed qPCR using independent 14 patients whose RNA were available (Replication group, Fig. 2). Although 
there was a gender difference (12 male vs 2 female) in the qPCR group, no statistically significant differences 
were observed between the expression levels of the 10 genes in males and females (P > 0.05). The expression 
levels in the replication group were similar to those in the RNA-seq group, and the expression levels of POSTN, 
arachidonate 15-lipoxygenase (ALOX15), cystatin SN (CST1), serpin peptidase inhibitor, clade B (ovalbumin), 
member3 (SERPINB3), CCL18, secretory leukocyte peptidase inhibitor (SLPI), BPI fold containing family B mem-
ber 1 (BPIFB1), statherin (STATH) and lactotransferrin (LTF) were significantly different in NP and IT samples 
(P < 0.05, Fig. 2). There was no significant difference between expression levels of the gene coding for BPI fold 
containing family A member 1 (BPIFA1) in NP and IT samples from the replication group (P > 0.05).
POSTN immunohistochemical analysis. We then focused on POSTN, whose expression was highest 
among the upregulated genes in the NP according to RNA-seq. To examine the association between POSTN 
protein expression level and CRSwNP subtype according to the JESREC scoring system, we performed immu-
nohistochemical analysis of NP obtained from 6 patients (RNA-seq group). POSTN deposition pattern in NP 
RNA-seq 
group
Replication 
group (qPCR)
Replication group 
(immunohistochemistry)
Serum biomarker 
group
Characteristics
   Subject no. 6 14 110 369
   Gender (M/F) 4/2 12/2 68/42 239/130
   Age (mean ± SD) 56.7 ± 15.0 57.4 ± 18.3 56.1 ± 14.7 53.7 ± 14.6
   Comorbid of asthma 2/6 (33.3%) 3/14 (21.4%) 31/110 (28.2%) 124/369 (33.6%)
Diagnosis
   Non-ECRS 2 6 34 122
   Mild ECRS 0 2 20 64
   Moderate ECRS 3 4 35 116
   Severe ECRS 1 2 21 67
Experiments
   RNA-seq 6 (−) (−) (−)
   qPCR 6 14 (−) (−)
   Immunohistochemistry 6 (−) 110 (−)
   ELISA (periostin) (−) (−) (−) 369
Table 1. Characteristics of subjects. RNA-seq, RNA sequencing; qPCR, quantitative real time PCR; ECRS, 
eosinophilic chronic rhinosinusitis.
Gene P value
Adjusted P value 
(FDR)
Log fold 
change NP (FPKM) IT (FPKM)
Upregulated
   POSTN 4.02 × 10−4 3.58 × 10−3 3.11 7.98 × 102 4.96 × 10
   ALOX15 3.92 × 10−3 2.21 × 10−2 3.07 6.34 × 102 8.02 × 10
   CST1 4.03 × 10−3 2.26 × 10−2 4.77 6.29 × 102 8.53
   SERPINB3 8.30 × 10−4 6.41 × 10−3 2.90 5.45 × 102 1.31 × 102
   CCL18 1.23 × 10−11 1.07 × 10−9 6.83 3.94 × 102 9.27 × 10−1
Downregulated
   BPIFA1 1.40 × 10−3 9.77 × 10−3 −3.01 4.13 × 103 2.66 × 104
   SLPI 9.77 × 10−7 2.63 × 10−5 −2.16 3.00 × 103 1.11 × 104
   BPIFB1 9.02 × 10−5 1.12 × 10−3 −2.74 2.02 × 103 1.18 × 104
   STATH 7.00 × 10−13 7.96 × 10−11 −10.8 9.14 × 102 6.71 × 104
   LTF 1.29 × 10−9 7.28 × 10−8 −4.47 8.27 × 102 6.92 × 103
Table 2. The 5 most upregulated and 5 most downregulated genes that were highly expressed in NP. Log 
fold change indicates the logarithm base 2 log fold change of count per million (CPM) mapped reads; NP, 
nasal polyp; IT, inferior turbinate; NP (FPKM) and IT (FPKM) represent averages of fragments per kilobase 
of transcript per million mapped fragments (FPKM) in NP and IT samples, respectively; POSTN, periostin; 
ALOX15, arachidonate 15-lipoxygenase; CST1, cystatin SN; SERPINB3, serpin peptidase inhibitor, clade B 
(ovalbumin), member3; CCL18, C-C motif chemokine ligand 18; BPIFA1, BPI fold containing family A member 
1; SLPI, secretory leukocyte peptidase inhibitor; BPIFB1, BPI fold containing family B member 1; STATH, 
statherin; LTF, lactotransferrin.
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was categorized based on the location of POSTN staining reported by Shiono et al.23 (Supplementary Fig. S1). 
POSTN staining pattern in NP tended to be more diffuse in those obtained from patients with more severe phe-
notypes (Supplementary Table S3). Furthermore, we performed immunohistochemical analysis using NP samples 
obtained independently from 110 patients with CRSwNP (Replication group) and IT samples obtained from 4 
patients undergoing septoplasty as control (Fig. 3). In the control group, POSTN deposition was observed only 
in the subepithelial layer, and the superficial type was observed more in CRSwNP from patients with a less severe 
phenotype than those with a more severe phenotype, and a significant difference in POSTN staining patterns was 
observed between the non-ECRS and severe ECRS subtypes (corrected P = 0.037).
Serum POSTN levels by ELISA. Next, we investigated the association between serum POSTN level and 
severity of CRSwNP to see whether serum POSTN is a possible biomarker for CRSwNP. First, we examined 
serum POSTN in each CRSwNP subtype (Fig. 4). The median (range) of serum POSTN in non-ECRS, mild 
ECRS, moderate ECRS and severe ECRS were 87.5 (28–245) ng/ml, 104.5 (54–259) ng/ml, 114 (40–325) ng/ml 
and 136 (48–369) ng/ml, respectively. Differences were statistically significant between all pairs of groups other 
than mild vs moderate and moderate vs severe ECRS (P < 0.05). Because patients with CRSwNP often have 
Figure 2. Relative expression levels of the 10 genes by qPCR analysis in the replication group (n = 14, Wilcoxon 
rank sum test). Bars show the median values and interquartile range. (a) The upregulated genes detected by 
RNA-seq (POSTN, ALOX15, CST1, SERPINB3 and CCL18). (b) The downregulated genes detected by RNA-seq 
(BPIFA1, SLPI, BPIFB1, STATH and LTF). NP, nasal polyp; IT, inferior turbinate; POSTN, periostin; ALOX15, 
arachidonate 15-lipoxygenase; CST1, cystatin SN; SERPINB3, serpin peptidase inhibitor, clade B (ovalbumin), 
member3; CCL18, C-C motif chemokine ligand 18; BPIFA1, BPI fold containing family A member 1; SLPI, 
secretory leukocyte peptidase inhibitor; BPIFB1, BPI fold containing family B member 1; STATH, statherin; 
LTF, lactotransferrin.
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asthma, and because serum POSTN is reportedly elevated in patients with asthma, we divided the patients into 
CRSwNP with and without asthma groups. The medians (range) of serum POSTN in the CRSwNP with and 
without asthma groups were 125.5 (48–369) ng/ml and 101 (28–325) ng/ml, respectively, and serum POSTN 
was significantly increased in the asthma group (P < 0.001). Second, we analyzed the correlation between serum 
POSTN and blood eosinophil percentage. We found a positive correlation between serum POSTN and blood 
eosinophil percentage (Fig. 5a, n = 369, r = 0.28, P < 0.001) and a positive correlation between serum POSTN and 
tissue eosinophil infiltration (Fig. 5b, n = 204, r = 0.26, P < 0.001).
Finally, we examined the association between serum POSTN and postoperative recurrence to see whether 
serum POSTN is a possible biomarker for postoperative recurrence. Receiver operating characteristics (ROC) 
curves were used to determine the cutoff point for postoperative recurrence (Fig. 6a). The area under the curve 
(AUC) was 0.595 (standard error: 0.044, 95% confidence interval: 0.509 to 0.681). Serum POSTN = 115.5 ng/ml 
was determined as the optimal cutoff point which were the closest to the top-left corner of ROC24 (sensitivity 
60.7%, specificity 61.9%). Kaplan-Meier plot of postoperative recurrence for whole CRS showed that there was a 
significant difference between these two groups when the cutoff point was set at 115.5 ng/ml (Fig. 6b, P = 0.0072). 
In the analysis restricted to non-CRS, the survival curve for POSTN high group and that for POSTN low group is 
different, but their trends were not statistically significant (Supplementary Fig. S3, P = 0.115).
Figure 3. Periostin deposition patterns in each group based on the immunohistochemical analysis. Chi-square 
test: *corrected P < 0.05. ECRS, eosinophilic chronic rhinosinusitis.
Figure 4. Serum periostin levels in the classified groups by the algorithm of JESREC study. Bars show the 
median values and interquartile range; Steel-Dwass’s test: *P < 0.05. ECRS, eosinophilic chronic rhinosinusitis.
www.nature.com/scientificreports/
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Discussion
In the present study, we identified genes differentially expressed in NP compared with IT by using RNA-seq tech-
nologies. Of these, the expression level of POSTN, ALOX15, CST1, SERPINB3, CCL18, SLPI, BPIFB1, STATH and 
LTF were validated to be statistically significantly different by qPCR analysis using independent NP/IT samples. 
We focused on POSTN whose expression level was the highest among the upregulated genes in RNA-seq and the 
results were validated in the replication samples. Additionally, we showed that serum POSTN is a biomarker of 
postoperative CRSwNP recurrence, and its optimal cut-off point was 115.5 ng/ml.
Figure 5. (a) Correlation between serum periostin level and blood eosinophil percentage. N = 369; Pearson 
correlation test: *r = 0.28, P < 0.001. (b) Correlation between serum periostin level and tissue eosinophil 
infiltration. N = 204; Pearson correlation test: *r = 0.26, P < 0.001. HPF, high-power field.
Figure 6. (a) ROC curve for postoperative recurrence to determine the cutoff point of serum periostin. (b) 
Kaplan–Meier curves of the relapse-free rate at the cutoff point of serum periostin 115.5 ng/ml; log-rank test: 
P = 0.0072. ROC, receiver operating characteristics.
www.nature.com/scientificreports/
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POSTN is an extracellular matrix protein belonging to the fasciclin family25,26, and is produced in fibroblasts 
and its expression level is controlled by IL-4, IL-13, TGF-β, connective tissue growth factor (CCN2/CTGF) 
and bone morphogenetic protein 2 (BMP-2)25–30. POSTN is directly attached to collagen type I, V, fibronectin, 
tenascin-C, and POSTN itself and this complex assists in subepithelial fibrosis and tissue remodeling26,30. It has 
been reported that POSTN is associated with Th2/eosinophilic inflammation31,32. In the present study, we per-
formed immunohistochemical analysis to determine the distribution of POSTN in NPs. We compared POSTN 
deposition pattern with phenotypes of CRSwNP diagnosed based on the criteria of the JESREC Study7. Shiono et al. 
reported that the POSTN deposition pattern was related with the number of infiltrated eosinophils in NPs23, 
which reflect the severity and poor outcome by treatment6,7. They also reported 2 types of POSTN deposition 
patterns based on the location of expression: superficial type, expressed only in the subepithelial layer; and diffuse 
type, expressed throughout the lamina propria starting just below the basement membrane23. In the present study, 
we found that the diffuse type of POSTN deposition was observed more in high-grade than in low-grade JESREC 
subtypes. High expression of POSTN has been reported in NPs of CRSwNP23,33–35, and POSTN expression level 
was positively correlated with IL-5 and IL-13, which may reflect Th2 type inflammation35,36. Our results empha-
sized the relationship between POSTN and Th2 inflammation in NPs.
Then, we investigated the association between serum POSTN level and severity of CRSwNP to see whether 
serum POSTN is a possible biomarker for CRSwNP. Serum POSTN was reported as a surrogate biomarker for 
the phenotype of Th2 high asthma31,32,37. Additionally, a recent study showed that serum POSTN was a biomarker 
of nasal polyps in patients with asthma38. We found that serum POSTN level was increased as patient’s severity 
increased, and that the significant difference was observed in serum POSTN level according to the severity of 
CRSwNP groups following the criteria of JESREC Study. Furthermore, serum POSTN level was positively corre-
lated with blood eosinophil percentage and tissue eosinophil infiltration. We previously reported that the percent-
age of postoperative recurrence in CRSwNP was 23.1% while that of severe ECRS by JESREC criteria was 51.8%7. 
In the present study, we found that serum POSTN level can be another candidate biomarker to predict postop-
erative recurrence. The optimal cutoff point was determined to be 115.5 ng/ml according to the closest point to 
top-left in ROC curve24. Izuhara et al. reported 95 ng/ml was optimal cutoff point for asthma when comparing 
with healthy control39. Serum POSTN was reported to be increased in inflammatory diseases such as idiopathic 
pulmonary fibrosis40 and atopic keratoconjunctitivitis41. Higher cutoff point of serum POSTN in CRSwNP than 
asthma might reflect local inflammation in nasal polyps. The level of serum POSTN in healthy controls averages 
66.1 ng/mL, as reported by Kimura et al.42. The JESREC score used in the present study is calculated based on 
unilateral or bilateral disease, the presence of NPs, the dominant shadow of ethmoid sinuses in CT scans, and 
the eosinophil ratio in peripheral blood7. In the presence of nasal polyps, serum POSTN levels were higher even 
in the non-ECRS group than in healthy controls. As reported by Tokunaga et al., the sensitivity and specificity 
of JESREC in distinguishing ECRS from non-ECRS were 83% and 66%, respectively7. The heterogeneity of CRS 
is now widely recognized, and as reviewed by Dennis et al., there are 4 distinct but overlapping classification 
schemes for defining endotypes of CRSwNP: the type 2 cytokine-based, eosinophil-based, IgE-based, and cystei-
nyl based approach43. Measurement of serum POSTN is simple and can be easily performed in hospitals and 
clinics, and our results suggested that serum POSTN is a biomarker of postoperative CRSwNP recurrence.
In the present study, we observed a statistically significant difference between serum POSTN levels in patients 
with CRSwNP and asthma and those without asthma. Serum POSTN levels are reportedly high in patients with 
CRSwNP and asthma44, but few reports have actually examined levels according to asthma status. Maxfield et al. 
examined serum POSTN levels in CRSwNP, CRSsNP, healthy subjects, and subjects who underwent endoscopic 
nasal surgery for conditions other than CRS45, and average serum POSTN levels were higher in CRSwNP with 
asthma than without, but it did not reach the statistical significance45. Our data support that asthma status influ-
ences serum POSTN levels in patients with CRSwNP.
In clinical trials, asthma exacerbations were effectively controlled by lebrikizumab treatment in patients 
with high serum POSTN levels, and lebrikizumab significantly improved FEV1 in these patients46. Additionally, 
Seshadri et al. reported a positive correlation between POSTN and IL-13 expression in NPs36. Therefore, lebriki-
zumab may be effective against refractory CRSwNP with high serum POSTN levels.
Recently, Wang et al. compared the expression levels of ECRSwNP with those of non-ECRSwNP by RNA-seq 
analysis, and found that gene expressions in ECRSwNP and non-ECRSwNP displayed distinct transcriptome 
profiles47. In Wang’s study, 41 genes with over 16-folds difference between ECRSwNP and non-ECRSwNP were 
reported; among them, CST1 and CCL18 were also differentially expressed between NP and IT in the present 
study. In Wang’s study, POSTN was not detected as a differentially expressed gene although they also examined 
gene expression levels in control tissues. This discrepancy may be due to the difference of control samples; we 
used IT while sphenoid mucosal tissues were collected as controls during endoscopic trans-sphenoid removal of 
nonfunctioning pituitary adenomas in the study by Wang et al.47.
In conclusion, we identified genes differentially expressed in NP compared with IT by using RNA-seq technol-
ogies. Protein expression levels of POSTN were associated with the severity of CRSwNP, and serum POSTN can 
be a novel biomarker for the postoperative recurrence of CRSwNP.
Methods
Ethics Statement. Informed consent was obtained from all of the patients. The ethical commit-
tees of Department of the Otorhinolaryngology Head & Neck Surgery, University of Fukui; Department of 
Otolaryngology Head & Neck Surgery, Okayama University Graduate School of Medicine; Department of 
Otolaryngology, Jichi Medical University, Saitama Medical Center; Department of Otorhinolaryngology Head 
& Neck Surgery, Dokkyo Medical University and Department of Otorhinolaryngology, Yokohama City Medical 
Center approved this research and study protocol. All methods were performed in accordance with the relevant 
guidelines and regulations.
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Patients and Sample collections. Patients with CRSwNP were diagnosed based on the clinical defini-
tion of rhinosinusitis in adults, EPOS 20122. CRSwNP were divided into 4 subtypes: non-ECRS, mild ECRS, 
moderate ECRS and severe ECRS following the criteria of JESREC study7. The study design and characteristics 
of subjects are shown in Table 1 and Fig. 1. In the RNA-seq group, 6 patients with CRSwNP undergoing the 
functional endoscopic sinus surgery were recruited at the Department of the Otorhinolaryngology Head & Neck 
Surgery, University of Fukui from January to September 2014. Fresh tissue samples of both NPs and ITs were 
collected from these 6 patients at the time of the surgery, and parts of the samples were immediately submerged 
in RNA later® (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and stored at −80 °C until use. These tissue 
samples were partly formalin-fixed and paraffin-embedded. In the replication group, 110 independent patients 
with CRSwNP undergoing functional endoscopic sinus surgery were also recruited at the Department of the 
Otorhinolaryngology Head & Neck Surgery, University of Fukui between January 1996 and April 2015. Fresh 
tissue samples of NPs and ITs were similarly collected and used for immunohistochemistry. Additionally, we 
collected 4 IT mucosa from independent patients undergoing septoplasty as controls for immunohistochemis-
try, none of whom suffered from CRSwNP nor allergic diseases. Fourteen paired NP and IT samples were used 
for qPCR analysis to validate the RNA-seq results. Serum samples from another 369 patients with CRSwNP 
undergoing functional endoscopic sinus surgery were collected at the 5 university hospitals (Department of 
the Otorhinolaryngology Head & Neck Surgery, University of Fukui; Department of Otolaryngology Head & 
Neck Surgery, Okayama University Graduate School of Medicine; Department of Otolaryngology, Jichi Medical 
University, Saitama Medical Center; Department of Otorhinolaryngology Head & Neck Surgery, Dokkyo Medical 
University and Department of Otorhinolaryngology, Yokohama City Medical Center) and stored at −20 °C until 
use. Postoperative recurrence was defined as the occurrence of condition with NPs or purulent discharge in 
middle meatus continuing for more than 28 days after the surgery and otorhinolaryngologists confirmed the 
diagnosis of postoperative recurrence using nasal endoscope.
Total RNA extraction. Frozen tissue specimens in RNA later® were transferred in 3 ml tubes (Yasui-kiki, 
Osaka, Japan) and immediately placed in liquid nitrogen. Then, tissue samples were powdered using Multi 
Beads Shocker® (Yasui-kiki) at 1700 rpm for 10 s. The powdered samples were dissolved in 1 ml TRIzol® reagent 
(Thermo Fisher Scientific Inc.) and RNA was isolated following the manufacturer’s protocol. Total RNA was 
extracted using Maxwell® 16 LEV simplyRNA Cells and Tissue Kit (Promega Corporation, Madison, WI, USA) 
following the manufacturer’s protocol or instruction, and eluted with 50 µl nuclease-free water. The extracted 
RNA was run on Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Santa Clara, CA, USA) to determine 
the quality of RNA. The RNA integrity numbers (RIN) were calculated using the Agilent 2100 Expert Software 
(Agilent Technologies). The RNA samples with RIN > 7 were used for RNA-seq and qPCR analysis.
RNA-seq experiment and data analysis. Libraries for sequencing were prepared with the total RNA 
using TruSeq RNA Sample Prep Kit (Illumina, Inc., San Diego, CA, USA) following the manufacturer’s protocol. 
Paired-end sequencing was performed with Illumina HiSeq. 2000 platform (Illumina). The raw data were mapped 
to the human reference genome (hg19) using TopHat 2.0.1448. The total number of reads aligned to each gene was 
obtained using the featureCounts function implemented in the Subread package for paired-end reads49. The read 
counts were imported into RStudio version 3.4.0 and processed with edgeR functions50. Differential expression 
analysis was individually performed on each paired sample using a negative binomial generalized linear model51. 
Fragments per kilobase of transcript per million mapped fragments (FPKM) values were calculated using the 
rpkm function in the edgeR package52. The cut-off value of differential expression was set based on the false 
discovery rate (q values, FDR)53 to P < 0.05 and a logarithm base 2 log fold change of count per million (CPM) 
mapped reads >1 or <−1. The datasets of the read counts are available at National Bioscience Database Center 
(NBDC, https://biosciencedbc.jp/ Research ID: hum0128).
Quantitative real time PCR. Reverse transcription and cDNA synthesis reactions were performed using 
500 ng of total RNA with High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific Inc.) fol-
lowing the manufacturer’s protocol. qPCR was performed using the TaqMan® Gene Expression Assays (Thermo 
Fisher Scientific Inc.): POSTN (Hs01566734_m1), ALOX15 (Hs00993765_g1), CST1 (Hs00606961_m1), 
SERPINB3 (Hs00199468_m1), CCL18 (Hs00268113_m1), BPIFA1 (Hs00213177_m1), SLPI (Hs00268204_m1), 
BPIFB1 (Hs00264197_m1), STATH (Hs00162389_m1) and LTF (Hs00914334_m1). The qPCR reaction mixture 
consisted of 5 µl qPCR QuickGoldStar Mastermix Plus (Eurogentec, Seraing, Belgium), 0.5 µl TaqMan® Gene 
Expression Assays, 0.5 µl nuclease free water and 4 µl diluted cDNA. The PCR reactions were 95 °C for 10 min, 
40 cycles at 92 °C for 15 s and 60 °C for 1 min. GAPDH was used as an internal standard using Pre-Developed 
TaqMan® Assay Reagents Human GAPDH (Thermo Fisher Scientific Inc.). Relative gene expression was calcu-
lated using the comparative Ct method (ΔΔCT Method) and normalized to that of GAPDH as an endogenous 
control54.
POSTN immunohistochemistry and ELISA. POSTN immunohistochemistry was performed as 
described previously26. Briefly, deparaffinized specimens were incubated with 0.2 µg/ml of mouse anti-POSTN 
monoclonal antibody (clone SS19C) at 4 °C overnight, followed by Horseradish peroxidase conjugated anti-rabbit/ 
mouse IgG secondary antibody (EnVision: Dako, Glostrup, Denmark) at RT for 1 h, and 3,3-diaminobenzidine 
tetrahydrochloride (DAB) development for approximately 20 s. The mouse anti-FLAG antibody was used as a 
control primary antibody, yielding no significant DAB staining. Some slides were stained at different days for 
intraexperimental reference purposes. The POSTN protein expressions in NPs were categorized based on the 
deposition patterns reported by Shiono et al.23 (see Supplementary Fig. S1); superficial type, expressed only in 
the subepithelial layer; diffuse type, expressed throughout the lamina propria starting just below the basement 
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membrane. Serum POSTN level was measured using POSTN ELISA Kit (Human) (Shino-test, Tokyo, Japan) 
according to the manufacturer’s protocol. The values were calculated at the absorbance of 450 nm.
Statistical analysis. Result of qPCR was analyzed using Wilcoxon rank sum test. We also performed sim-
ple linear regression analysis to determine whether gender differences influenced gene expression. Differences 
in immunohistochemical staining patterns between the non-ECRS and each ECRS group were assessed 
by chi-squared tests, and the Bonferroni correction was applied to comparisons between multiple groups. 
Comparisons between serum POSTN levels in CRSwNP with and without asthma were made using the 
Mann-Whitney test. The comparisons among the serum POSTN in each group of CRS was performed using 
Steel-Dwass multiple comparisons test. Correlation between serum POSTN and serum eosinophil was assessed 
using Spearman’s rank correlation. To analyze the relation between serum POSTN and postoperative recurrence, 
ROC curves were used, and the closest point to top-left of ROC was determined as the optimal cut-off point24. 
Relapse-free survival curves of postoperative recurrence were drawn using the Kaplan-Meier method. A P value 
or an adjusted P value of < 0.05 was considered statistically significant.
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